Article info
PDFReviews
When the going gets tough: how to select patients with Parkinson's disease for advanced therapies
- Correspondence to Dr Paul F Worth, Department of Neurology, Norfolk and Norwich Hospital NHS Foundation Trust, Colney Lane, Norwich NR4 7UY, UK; paul.worth{at}nnuh.nhs.uk
Citation
When the going gets tough: how to select patients with Parkinson's disease for advanced therapies
Publication history
- Received November 9, 2012
- First published March 13, 2013.
Online issue publication
February 28, 2018
Article Versions
- Previous version (14 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- Parkinson’s disease: etiopathogenesis and treatment
- Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease
- Deep brain stimulation for movement disorders
- Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson’s disease patients previously reliant on apomorphine
- Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson's disease using an MRI-guided and MRI-verified approach
- Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson’s disease 4 years after surgery: double blind and open label evaluation
- Emergencies and critical issues in Parkinson’s disease
- Effects of subthalamic deep brain stimulation on dysarthrophonia in Parkinson’s disease
- A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson’s disease: results at the 36-month follow-up
- Different patterns of medication change after subthalamic or pallidal stimulation for Parkinson’s disease: target related effect or selection bias?